Medtronic reports first quarter fiscal 2025 financial results

Goldman Sachs Reiterates Sell Rating on Medtronic, Inc. (MDT)

Goldman Sachs analyst David Roman reiterated a Sell rating and $82.00 price target on Medtronic, Inc. (NYSE: MDT)

The analyst comments "Following 1QFY25, we revise our model for (1) recent business performance; (2) updated market outlooks and competitive positioning; and (3) P&L assumptions. For FY25, we land just below EBIT margin targets, driven by sustained... More

Medtronic, Inc. (MDT) PT Raised to $94 at Oppenheimer

Oppenheimer analyst Steven Lichtman raised the price target on Medtronic, Inc. (NYSE: MDT) to $94.00 (from $92.00) while maintaining a Perform rating.

The analyst comments "Medtronic raised FY25 guidance low-end on organic sales (4.5-5% vs. 4-5% prior) and EPS (up slightly to $5.42-5.50 vs. $5.405.50). F1Q... More

Medtronic, Inc. (MDT) PT Raised to $106 at Wells Fargo

Wells Fargo analyst Larry Biegelsen raised the price target on Medtronic, Inc. (NYSE: MDT) to $106.00 (from $105.00) while maintaining a Overweight rating.

The analyst comments "Strong FQ1 rev beat on CVG, Neuroscience, and Diabetes strength. MDT reported FQ1 2025 rev of $8.0B (+5.3% organic) exceeded... More

Wolfe Research Reiterates Underperform Rating on Medtronic, Inc. (MDT)

Wolfe Research analyst Mike Polark reiterated an Underperform rating and $82.00 price target on Medtronic, Inc. (NYSE: MDT).

The analyst comments "We rate MDT shares Underperform. We have an $82 target price which simplistically represents a 15x multiple on our FY2025 adjusted EPS forecast. On FY2025 EPS, our 15 P/E input represents a ~25% discount to current CY25 S&P 500 multiple of ~20x. This discount to the S&P sits in bottom quartile of the last decade. A discount is warranted, in our view, on track record and short-run expectations. Back 12 years, MDT EPS has... More

Deutsche Bank Reiterates Hold Rating on Medtronic, Inc. (MDT)

Deutsche Bank analyst Pito Chickering reiterated a Hold rating and $85.00 price target on Medtronic, Inc. (NYSE: MDT)

The analyst comments "MDT outperformed the broader market by 100 bps post this mornings print, with shareholders frustrated that MDT didnt outperform more post the beat-and-raise. MDT now... More

Medtronic hikes fiscal 2025 guidance as Q1 earnings beat expectations

Medtronic (NYSE: MDT) reported first-quarter earnings that surpassed expectations and raised the outlook for the full fiscal 2025. The companys shares rose marginally in the premarket trade Tuesday.

For Q1, Medtronic reported earnings per share (EPS) of $1.23, topping the analyst estimate of $1.20. The company's revenue for the quarter matched the consensus estimate, coming in at $7.9 billion.

In its Cardiovascular segment, Medtronic generated $3.01 billion in... More